| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| HLA-G & B2M & Peptide (RIIPRHLQL) | Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein (MALS verified) | Human | HEK293 | MALSSDS-PAGE | $335.00 25ug | |||
| HLA-G & B2M & Peptide (RIIPRHLQL) | Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Osugacestat | AL-101(BMS); BMS-906024 | Phase 2 Clinical | Bristol-Myers Squibb Company, Glaxosmithkline Plc | Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 상세 |